Evidence map›Paper›PMID 28654376›Full record

ArticleMolecular imaging2017

Preclinical Evaluation of

Emre Demirci, Rafay Ahmed, Meltem Ocak, Joseph Latoche, April Radelet, Nicole DeBlasio, N Scott Mason, Carolyn J Anderson, James M Mountz

Open access · goldAbstract read
In one paragraph

Article in Molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Preclinical PET, PET/CT, and PET/MRI.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026
    Review
  2. Article
  3. Review
  4. Interest and Limits of [Frontiers in oncology · 2021
    Review
  5. [EJNMMI research · 2020
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Emre Demirci1 Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA.
Rafay Ahmed1 Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA.
Meltem Ocak1 Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA.
Joseph Latoche1 Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA.
April Radelet1 Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA.
Nicole DeBlasio1 Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA.
N Scott Mason1 Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA.
Carolyn J Anderson1 Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA.
James M Mountz1 Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA.
University of Pittsburgh · USŞişli Etfal Eğitim ve Araştırma Hastanesi · TR

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Jessie Nedrow · 1988 to 2026
$158.0M
Quantitative Biomarker Imaging for Early Therapy Response Assessment in CancerU01CA140230 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MOUNTZ, JAMES M. · 2009 to 2013
$2.1M
NCI NIH HHS P30 CA047904NCI NIH HHS U01 CA140230
6 · The paper itself

Abstract

purposeWe investigated 2-(5-fluoro-pentyl)-2-methyl-malonic acid ( PROCEDURES: BALB/c nude mice (4-8 weeks old) were implanted with UM-SCC-22B tumors. The treatment group received 2 doses of doxorubicin (10 mg/kg, days 0, 2). Small animal

resultsTreated mice demonstrated increased

conclusion2-(5-Fluoro-pentyl)-2-methyl-malonic acid PET imaging has the potential for early assessment of treatment-induced apoptosis. Timing and image analysis strategies may require optimization, depending on the type of tumor and cancer treatment.

Indexed as

AnimalsApoptosisCell Line, TumorDoxorubicinFemaleFluorodeoxyglucose F18HumansImmunohistochemistryMethylmalonic AcidMiceMice, Inbred BALB CMice, NudePositron-Emission TomographyTomography, X-Ray ComputedXenograft Model Antitumor Assays5-fluoropentyl-2-methylmalonic acidDoxorubicinFluorodeoxyglucose F18Methylmalonic Acid18F-ML-10apoptosisearly responsemolecular imagingPET

Identifiers

PMID28654376
PMCPMC5469516
OpenAlexW2574061671

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.